Celltrion presents positive RWE on switching from IV to SC infliximab

South Korean biosimilars company Celltrion (KRX: 068270) has presented real-world evidence (RWE) supporting the use of subcutaneous (SC) infliximab, confirming the efficacy and safety of switching to SC infliximab 120mg every two weeks in patients with inflammatory bowel disease (IBD).

Originally sold by Johnson & Johnson (NYSE: JNJ) under the brand name Remicade among others, infliximab is a biologic medication that is also used to treat autoimmune diseases like Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

Celltrion’s RWE was presented at the Meet the Expert Sessions at UEG 2025, and included presentations from Nicolas Mathieu, medical director of MICI Institut Privé, Cliniques des Cèdres and associate professor of Gastroenterology, and Anthony Buisson, head of the IBD Unit at University Hospital Estaing, Clermont Ferrand, France.